The transthyretin amyloidosis treatment market share analysis is undergoing a revolutionary transformation, driven by rapid innovation, regulatory approvals, and the increasing global focus on rare diseases. With an impressive projected CAGR of 8.9%, the market is set to reach a valuation of USD 6.64 billion by 2025. As healthcare systems shift their priorities toward rare …